Galectin-3 is not useful in thyroid FNA

Cytopathology

Volumn 16, Issue 3, 2005, Pages 132-138

  Mills, L J ^a   Poller, D N ^a   Yiangou, C ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Carcinoma; Cytology; Galectin 3; Negative staining; Thyroid FNA

Indexed keywords

GALECTIN 3;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; DIAGNOSTIC VALUE; FEMALE; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS;

EID: 20444449623     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2005.00213.x     Document Type: Article

References (25)

1. Barondes SH, Cooper DNW, Gilt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-10.
2. Baldus SE, Zirbes TK, Weingarten M et al. Increased Galectin-3 expression in gastric cancer: correlation with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumor Biol 2000;21:258-66.
3. Irimura T, Matsushita Y, Sutton RC et al. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991;51:387-93.
4. Castronovo V, Brule FAV, Jackers P et al. Decreased expression of galectin 3 is associated with progression of human breast cancer. J Pathol 1996;179:43-8.
5. Inohara H, Honjo Y, Yoshii T et al. Expression of Galectin-3 in fine-needle aspirates as a diagnostic marker for differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-84.
6. Gasbarri A, Martengani MP, Del Prete F, Lucatne T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-502.
7. Saggiorato E, Cappia S, De Giuli P et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5152-8.
8. Giannini R, Faviana P, Cavinato T et al. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 2003;13:765-70.
9. Fernandez PL, Merino MJ, Gomez M et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997;181:80-6.
10. Orlandi F, Saggiorato E, Pivano G et al. Galectin 3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998;58:3015-20.
11. Bartolazzi A, Gasbarri A, Papotti M et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
12. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin 1 and galectin 3 in thyroid tumours. Potential diagnostic implications. Am J Pathol 1995;147:815-22.
13. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW. Immunohistochemical expression of galectin 3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-3.
14. Martins L, Matsuo SE, Ebina KN, Kulcsar MAV, Friguglietti CUM, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumours. J Clin Endocrinol Metab 2002;87:4806-10.
15. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and thyroid papillary carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3 and HBMB-1. Endocr Pathol 2003;14:55-9.
16. Kawachi K, Matsushita Y, Yonezawa S et al. Galectin 3 expression in various thyroid neoplasms and its possible role in metastasis formation. Human Pathol 2000;31:428-433.
17. Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z. The investigation of galectin 3 in disease of the thyroid gland. Eur J Endocrinol 2003;149:449-53.
18. Niedziela M, Maceluch J, Korman E. Galectin 3 is not a universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab 2002;87:4411-5.
19. Takano T, Miyauchi A, Mattsuzuka F, Yoshida H, Kuma K, Amino N. Ubiquitous expression of galectin 3 mRNA in benign and malignant thyroid tumors. Cancer Lett 2003;199:69-73.
20. Beesley MF, McLaren KM. Cytokeratin 19 and galectin 3 immunohistochemistry in the differential diagnosis of solid thyroid nodules. Histopathology 2002;41:236-43.
21. Coli A, Biogotti G, Zucchetti F, Negro F, Massi G. Galectin 3, a marker of well differentiated thyroid carcinoma is expressed in thyroid nodules with cytological atypia. Histopathology 2002;40:80-7.
22. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin 3 in malignant and benign human thyroid tissue. Anticancer Res 1998;18:2637-42.
23. Feilchenfeldt J, Totsch M, Sheu SY et al. Expression of galectin 3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol 2003;16:1117-23.
24. Davies R, Dina R. Galectin 3 in thyroid nodules: a cytohistological correlation. Cytopathology 2003;14:9 (abstr).
25. Poller DN, Ibrahim AK, Cummings MH, Mikel JJ, Boote D, Perry M. Fine needle aspiration of the thyroid: importance of an indeterminate diagnostic category. Cancer 2000;90:239-44.